F44-A13
Product Specifications
UNSPSC Description
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders[1].
Target Antigen
Cytochrome P450; FXR; PPAR; RAR/RXR; ROR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/f44-a13.html
Purity
96.73
Solubility
10 mM in DMSO
Smiles
CCN(C1=CC(OS(=O)(C2=CC=C(C=C2)NC(C)=O)=O)=C(C=C1)CN(C(NC(C)(C)C)=O)CC3CC3)CC
Molecular Weight
544.71
References & Citations
[1]Dou X, et al. Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation. Eur J Med Chem. 2024;269:116323.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-163436/F44-A13-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-163436/F44-A13-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1338190-14-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
